Cover Image
市場調查報告書

大塚集團:產品平台分析

Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 256025
出版日期 內容資訊 英文 122 Pages
訂單完成後即時交付
價格
Back to Top
大塚集團:產品平台分析 Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016
出版日期: 2016年03月30日 內容資訊: 英文 122 Pages
簡介

大塚集團是日本的控股公司,在以醫藥品為首、營養補給品、消費品等各種產業上發展事業。該公司的產品系列有醫藥品,化妝品,機能性食品·飲料,酒精飲料,精細化學品,電子設備,功能性化學產品,醫療設備,成藥等。

本報告提供大塚集團的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

大塚集團的基本資料

  • 大塚集團概要
  • 主要資訊
  • 企業資料

大塚集團:R&D概要

  • 主要的治療範圍

大塚集團:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

大塚集團:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

大塚集團:藥物簡介

  • (tipiracil hydrochloride + trifluridine)
  • aripiprazole
  • brexpiprazole
  • tolvaptan
  • trabectedin
  • (aripiprazole + sertraline)
  • (carteolol hydrochloride + latanoprost)
  • delamanid
  • nabiximols
  • rebamipide
  • (dextromethorphan hydrobromide + quinidine sulfate)
  • AVP-786
  • OCV-101
  • OCV-501
  • OPA-15406
  • probucol
  • tetomilast
  • OPA-6566
  • OPB-111001
  • OPB-31121
  • LPC-01
  • OCVC-02
  • OPB-111077
  • OPB-51602
  • OPC-108459
  • OPS-2071

大塚集團:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

大塚集團:最近的開發平台趨勢

大塚集團:暫停中的計劃

大塚集團:開發中止的開發中產品

  • 開發中止的開發中產品簡介
  • (tipiracil hydrochloride + trifluridine)
  • AVP-13358
  • AZD-2479
  • rebamipide

大塚集團:企業發表

大塚集團:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08010CDB

Summary

Global Markets Direct's, 'Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Otsuka Holdings Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Otsuka Holdings Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Otsuka Holdings Co., Ltd.
  • The report provides overview of Otsuka Holdings Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Otsuka Holdings Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Otsuka Holdings Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Otsuka Holdings Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Otsuka Holdings Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Otsuka Holdings Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Otsuka Holdings Co., Ltd. Snapshot
    • Otsuka Holdings Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Otsuka Holdings Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Otsuka Holdings Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Otsuka Holdings Co., Ltd. - Pipeline Products Glance
    • Otsuka Holdings Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Otsuka Holdings Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Otsuka Holdings Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Otsuka Holdings Co., Ltd. - Drug Profiles
    • (carteolol hydrochloride + latanoprost)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (tipiracil hydrochloride + trifluridine)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levetiracetam
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ponatinib hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tolvaptan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (aripiprazole + sertraline)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (gimeracil + oteracil + tegafur)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • aripiprazole ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AVP-786
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brexpiprazole
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • delamanid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nabiximols
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rebamipide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (dextromethorphan + quinidine sulfate)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OCV-501
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPA-15406
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPS-2071
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • probucol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tetomilast
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPA-6566
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPB-111001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LPC-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LUAF-20513
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OCVC-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPB-111077
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPC-108459
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPC-39436
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPC-64005
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPC-28326
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Otsuka Holdings Co., Ltd. - Pipeline Analysis
    • Otsuka Holdings Co., Ltd. - Pipeline Products by Target
    • Otsuka Holdings Co., Ltd. - Pipeline Products by Route of Administration
    • Otsuka Holdings Co., Ltd. - Pipeline Products by Molecule Type
    • Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action
  • Otsuka Holdings Co., Ltd. - Recent Pipeline Updates
  • Otsuka Holdings Co., Ltd. - Dormant Projects
  • Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • (gimeracil + oteracil + tegafur)
      • (tipiracil hydrochloride + trifluridine)
      • AVP-13358
      • AZD-2479
      • brexpiprazole
      • dasatinib
      • OCV-101
      • OPB-31121
      • OPB-51602
      • rebamipide
  • Otsuka Holdings Co., Ltd. - Company Statement
  • Otsuka Holdings Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Otsuka Holdings Co., Ltd., Key Information
  • Otsuka Holdings Co., Ltd., Key Facts
  • Otsuka Holdings Co., Ltd. - Pipeline by Indication, 2016
  • Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2016
  • Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2016
  • Otsuka Holdings Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Otsuka Holdings Co., Ltd. - Pre-Registration, 2016
  • Otsuka Holdings Co., Ltd. - Phase III, 2016
  • Otsuka Holdings Co., Ltd. - Phase II, 2016
  • Otsuka Holdings Co., Ltd. - Phase I, 2016
  • Otsuka Holdings Co., Ltd. - Preclinical, 2016
  • Otsuka Holdings Co., Ltd. - Pipeline by Target, 2016
  • Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2016
  • Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2016
  • Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Otsuka Holdings Co., Ltd. - Recent Pipeline Updates, 2016
  • Otsuka Holdings Co., Ltd. - Dormant Developmental Projects,2016
  • Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products, 2016
  • Otsuka Holdings Co., Ltd., Other Locations
  • Otsuka Holdings Co., Ltd., Subsidiaries

List of Figures

  • Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2016
  • Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2016
  • Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Target, 2016
  • Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2016
  • Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2016
  • Otsuka Holdings Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top